Deutsche Bank analyst David Hoang lowered the firm’s price target on Sarepta (SRPT) to $70 from $99 and keeps a Hold rating on the shares ahead of the Q1 report. Sarepta “continues to be a falling knife,” impacted “by a confluence of negative events,” the analyst tells investors in a research note. The firm sees a “rough road ahead” for Elevidys.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Paramount downgraded, Broadcom upgraded: Wall Street’s top analyst calls
- Sarepta upgraded to Neutral from Sell at H.C. Wainwright
- Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
- Sarepta price target lowered to $179 from $210 at BofA
- Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz